Pathogenesis of neointima formation following vascular injury

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 11, Issue 1, 2011, Pages 30-39

  Pourdjabbar, Ali ^a   Hibbert, Benjamin ^a   Simard, Trevor ^a   Ma, Xiaoli ^a   O'Brien, Edward R ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Endothelial cell; Endothelial progenitor cell; In stent restenosis; Neointima; Smooth muscle cell; Vascular progenitor cell

Indexed keywords

ADVENTITIA; BLOOD VESSEL INJURY; CELL MIGRATION; CELL PROLIFERATION; DRUG ELUTING STENT; ENDOTHELIUM CELL; HUMAN; INTIMA; MEDICAL RESEARCH; NEOINTIMA; NONHUMAN; PATHOGENESIS; REVIEW; SMOOTH MUSCLE FIBER; STEM CELL; STENT;

EID: 79959312607     PISSN: 1871529X     EISSN: 1871529X     Source Type: Journal    
DOI: 10.2174/187152911795945169     Document Type: Review

References (124)

1. Manuel, D.G.; Leung, M.; Nguyen, K.; Tanuseputro, P.; Johansen, H. Burden of cardiovascular disease in Canada. Can J. Cardiol., 2003, 19(9), 997-1004.
2. Macaya, C.; Serruys, P.W.; Ruygrok, P.; Suryapranata, H.; Mast, G.; Klugmann, S.; Urban, P.; den, H.P.; Koch, K.; Simon, R.; Morice, M.C.; Crean, P.; Bonnier, H.; Wijns, W.; Danchin, N.; Bourdonnec, C.; Morel, M.A. Continued benefit of coronary stenting versus balloon angioplasty: one-year clinical follow-up of Benestent trial. Benestent Study Group. J. Am. Coll. Cardiol., 1996, 27(2), 255-261.
3. Grines, C.L.; Cox, D.A.; Stone, G.W.; Garcia, E.; Mattos, L.A.; Giambartolomei, A.; Brodie, B.R.; Madonna, O.; Eijgelshoven, M.; Lansky, A.J.; O'Neill, W.W.; Morice, M.C., Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N. Engl. J. Med., 1999, 341(26), 1949-1956.
4. Froeschl, M.; Olsen, S.; Ma, X.; O'Brien, E.R. Current understanding of in-stent restenosis and the potential benefit of drug eluting stents. Curr. Drug Targets Cardiovasc. Haematol. Disord., 2004, 4(1), 103-117.
5. W.S. The pathophysiology and burden of restenosis. Am. J. Cardiol., 2007, 100(5A), 3K-9K.
6. Lloyd-Jones, D.; Adams, R.; Carnethon, M.; De, S.G.; Ferguson, T.B.; Flegal, K.; Ford, E.; Furie, K.; Go, A.; Greenlund, K.; Haase, N.; Hailpern, S.; Ho, M.; Howard, V.; Kissela, B.; Kittner, S.; Lackland, D.; Lisabeth, L.; Marelli, A.; McDermott, M.; Meigs, J.; Mozaffarian, D.; Nichol, G.; O'Donnell, C.; Roger, V.; Rosamond, W.; Sacco, R.; Sorlie, P.; Stafford, R.; Steinberger, J.; Thom, T.; Wasserthiel-Smoller, S.; Wong, N.; Wylie-Rosett, J.; Hong, Y., Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 2009, 119(3), e21-181.
7. Tu, J.V.; Austin, P.C.; Filate, W.A.; Johansen, H.L.; Brien, S.E.; Pilote, L.; Alter, D.A. Outcomes of acute myocardial infarction in Canada. Can. J. Cardiol., 2003, 19(8), 893-901.
8. Ko, D.T.; Donovan, L.R.; Huynh, T.; Rinfret, S.; So, D.Y.; Love, M.P.; Galbraith, D.; Tu, J.V. A survey of primary percutaneous coronary intervention for patients with ST segment elevation myocardial infarction in Canadian hospitals. Can. J. Cardiol., 2008, 24(11), 839-843.
9. Bittl, J.A. Advances in coronary angioplasty. N. Engl. J. Med., 1996, 335(17), 1290-1302.
10. Serruys, P.W.; Luijten, H.E.; Beatt, K.J.; Geuskens, R.; de Feyter, P.J.; van den, B.M.; Reiber, J.H.; ten Katen, H.J.; van Es, G.A.; Hugenholtz, P.G. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation, 1988, 77(2), 361-371.
11. Serruys, P.W.; Strauss, B.H.; Beatt, K.J.; Bertrand, M.E.; Puel, J.; Rickards, A.F.; Meier, B.; Goy, J.J.; Vogt, P.; Kappenberger, L. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N. Engl. J. Med., 1991, 324(1), 13-17.
12. Fischman, D.L.; Savage, M.P.; Goldberg, S. Coronary stent placement in patients with de-novo and restenotic native coronary artery lesions. Coron Artery Dis., 1994, 5(7), 571-574.
13. Gershlick, A.H.; Baron, J. Dealing with in-stent restenosis. Heart, 1998, 79(4), 319-323.
14. Bhargava, B.; Karthikeyan, G.; Abizaid, A.S.; Mehran, R. New approaches to preventing restenosis. BMJ, 2003, 327(7409), 274-279.
15. Morice, M.C.; Serruys, P.W.; Sousa, J.E.; Fajadet, J.; Ban, H.E.; Perin, M.; Colombo, A.; Schuler, G.; Barragan, P.; Guagliumi, G.; Molnar, F.; Falotico, R. A randomized comparison of a sirolimuseluting stent with a standard stent for coronary revascularization. N. Engl. J. Med., 2002, 346(23), 1773-1780.
16. Moses, J.W.; Leon, M.B.; Popma, J.J.; Fitzgerald, P.J.; Holmes, D.R.; O'Shaughnessy, C.; Caputo, R.P.; Kereiakes, D.J.; Williams, D.O.; Teirstein, P.S.; Jaeger, J.L.; Kuntz, R.E. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med, 2003, 349(14), 1315-1323.
17. Stone, G.W.; Ellis, S.G.; Cox, D.A.; Hermiller, J.; O'Shaughnessy, C.; Mann, J.T.; Turco, M.; Caputo, R.; Bergin, P.; Greenberg, J.; Popma, J.J.; Russell, M.E. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med, 2004, 350(3), 221-231.
18. Stone, G.W.; Moses, J.W.; Ellis, S.G.; Schofer, J.; Dawkins, K.D.; Morice, M.C.; Colombo, A.; Schampaert, E.; Grube, E.; Kirtane, A.J.; Cutlip, D.E.; Fahy, M.; Pocock, S.J.; Mehran, R.; Leon, M.B. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med, 2007, 356(10), 998-1008.
19. James, S.K.; Stenestrand, U.; Lindback, J.; Carlsson, J.; Schersten, F.; Nilsson, T.; Wallentin, L.; Lagerqvist, B. Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden. N Engl J Med, 2009, 360(19), 1933-1945.
20. Hibbert, B.; Ma, X.; Pourdjabbar, A.; Holm, E.; Rayner, K.; Chen, Y.X.; Sun, J.; Filion, L.; O'Brien, E.R. Inhibition of endothelial progenitor cell glycogen synthase kinase-3beta results in attenuated neointima formation and enhanced re-endothelialization after arterial injury. Cardiovasc. Res., 2009, 83(1), 16-23.
21. Ma, X.; Hibbert, B.; Dhaliwal, B.; Seibert, T.; Chen, Y.X.; Zhao, X.; O'Brien, E.R. Delayed re-endothelialization with rapamycincoated stents is rescued by the addition of a glycogen synthase kinase-3beta inhibitor. Cardiovasc. Res., 2010, 86(2), 338-345.
22. Klomp, M.; Beijk, M.A.; de Winter, R.J. Genous endothelial progenitor cell-capturing stent system: a novel stent technology. Expert Rev. Med. Devices, 2009, 6(4), 365-375.
23. Beijk, M.A.; Klomp, M.; Verouden, N.J.; van, G.N.; Koch, K.T.; Henriques, J.P.; Baan, J.; Vis, M.M.; Scheunhage, E.; Piek, J.J.; Tijssen, J.G.; de Winter, R.J. Genous endothelial progenitor cell capturing stent vs. the Taxus Liberte stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study. Eur. Heart J., 2010, 31(9), 1055-1064.
24. Glover, C.; Ma, X.; Chen, Y.X.; Miller, H.; Veinot, J.; Labinaz, M.; O'Brien, E. Human in-stent restenosis tissue obtained by means of coronary atherectomy consists of an abundant proteoglycan matrix with a paucity of cell proliferation. Am. Heart J., 2002, 144(4), 702-709.
25. Glover, C.; O'Brien, E.R. Pathophysiological insights from studies of retrieved coronary atherectomy tissue. Semin. Interv. Cardiol., 2000, 5(4), 167-173.
26. Ross, R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 1993, 362(6423), 801-809.
27. Owens, G.K.; Kumar, M.S.; Wamhoff, B.R. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol. Rev., 2004, 84(3), 767-801.
28. Jevon, M.; Dorling, A.; Hornick, P.I. Progenitor cells and vascular disease. Cell Prolif, 2008, 41(S1), 146-164.
29. Hirschi, K.K.; Ingram, D.A.; Yoder, M.C. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler. Thromb. Vasc. Biol., 2008, 28(9), 1584-1595.
30. Padfield, G.J.; Newby, D.E.; Mills, N.L. Understanding the role of endothelial progenitor cells in percutaneous coronary intervention. J. Am. Coll. Cardiol., 2010, 55(15), 1553-1565.
31. Hibbert, B.; Olsen, S.; O'Brien, E. Involvement of progenitor cells in vascular repair. Trends Cardiovasc. Med., 2003, 13(8), 322-326.
32. Hillebrands, J.L.; Onuta, G.; Rozing, J. Role of progenitor cells in transplant arteriosclerosis. Trends Cardiovasc. Med., 2005, 15(1), 1-8.
33. Clowes, A.W.; Reidy, M.A.; Clowes, M.M. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab. Invest., 1983, 49(3), 327-333.
34. Clowes, A.W.; Reidy, M.A.; Clowes, M.M. Mechanisms of stenosis after arterial injury. Lab. Invest., 1983, 49(2), 208-215.
35. Benditt, E.P.; Benditt, J.M. Evidence for a monoclonal origin of human atherosclerotic plaques. Proc. Natl. Acad. Sci. USA, 1973, 70(6), 1753-1756.
36. Pearson, T.A.; Dillman, J.; Williams, K.J.; Wolff, J.A.; Adams, R.; Solez, K.; Heptinstall, R.H.; Malmros, H.; Sternby, N. Clonal characteristics of experimentally induced atherosclerotic lesions in the hybrid hare. Science, 1979, 206(4425), 1423-1425.
37. Pearson, T.A.; Dillman, J.; Solez, K.; Heptinstall, R.H. Monoclonal characteristics of organising arterial thrombi: Significance in the origin and growth of human atherosclerotic plaques. Lancet, 1979, 1(8106), 7-11.
38. Gordon, D.; Reidy, M.A.; Benditt, E.P.; Schwartz, S.M. Cell proliferation in human coronary arteries. Proc. Natl. Acad. Sci. USA, 1990, 87(12), 4600-4604.
39. Marek, J.M.; Koehler, C.; Aguirre, M.L.; Westerband, A.; Gentile, A.T.; Mills, J.L.; Hunter, G.C. The histologic characteristics of primary and restenotic carotid plaque. J. Surg. Res., 1998, 74(1), 27-33.
40. O'Brien, E.R.; Alpers, C.E.; Stewart, D.K.; Ferguson, M.; Tran, N.; Gordon, D.; Benditt, E.P.; Hinohara, T.; Simpson, J.B.; Schwartz, S.M. Proliferation in primary and restenotic coronary atherectomy tissue. Implications for antiproliferative therapy. Circ. Res., 1993, 73(2), 223-231.
41. Schwartz, S.M.; deBlois, D.; O'Brien, E.R. The intima. Soil for atherosclerosis and restenosis. Circ. Res., 1995, 77(3), 445-465.
42. Schwartz, S.M. Smooth muscle migration in atherosclerosis and restenosis. J. Clin. Invest., 1997, 100(11 Suppl), S87-S89.
43. Kokubo, T.; Uchida, H.; Choi, E.T. Integrin alpha(v)beta(3) as a target in the prevention of neointimal hyperplasia. J. Vasc. Surg., 2007, 45(Suppl A), A33-A38.
44. Zargham, R.; Thibault, G. alpha8beta1 Integrin expression in the rat carotid artery: involvement in smooth muscle cell migration and neointima formation. Cardiovasc. Res., 2005, 65(4), 813-822.
45. Jalvy, S.; Renault, M.A.; Leen, L.L.; Belloc, I.; Bonnet, J.; Gadeau, A.P.; Desgranges, C. Autocrine expression of osteopontin contributes to PDGF-mediated arterial smooth muscle cell migration. Cardiovasc. Res., 2007, 75(4), 738-747.
46. Bayless, K.J.; Meininger, G.A.; Scholtz, J.M.; Davis, G.E. Osteopontin is a ligand for the alpha4beta1 integrin. J. Cell Sci., 1998, 111(9), 1165-1174.
47. Ikeda, T.; Shirasawa, T.; Esaki, Y.; Yoshiki, S.; Hirokawa, K. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J. Clin. Invest., 1993, 92(6), 2814-2820.
48. Liaw, L.; Skinner, M.P.; Raines, E.W.; Ross, R.; Cheresh, D.A.; Schwartz, S.M.; Giachelli, C.M. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J. Clin. Invest., 1995, 95(2), 713-724.
49. Corjay, M.H.; Diamond, S.M.; Schlingmann, K.L.; Gibbs, S.K.; Stoltenborg, J.K.; Racanelli, A.L. alphavbeta3, alphavbeta5, and osteopontin are coordinately upregulated at early time points in a rabbit model of neointima formation. J. Cell Biochem., 1999, 75(3), 492-504.
50. Giachelli, C.M.; Liaw, L.; Murry, C.E.; Schwartz, S.M.; Almeida, M. Osteopontin expression in cardiovascular diseases. Ann. NY Acad. Sci., 1995, 760, 109-126.
51. Giachelli, C.M.; Bae, N.; Almeida, M.; Denhardt, D.T.; Alpers, C.E.; Schwartz, S.M. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J. Clin. Invest., 1993, 92(4), 1686-1696.
52. Han, M.; Wen, J.K.; Zheng, B.; Liu, Z.; Chen, Y. Blockade of integrin beta3-FAK signaling pathway activated by osteopontin inhibits neointimal formation after balloon injury. Cardiovasc. Pathol., 2007, 16(5), 283-290.
53. Liaw, L.; Lombardi, D.M.; Almeida, M.M.; Schwartz, S.M.; deBlois, D.; Giachelli, C.M. Neutralizing antibodies directed against osteopontin inhibit rat carotid neointimal thickening after endothelial denudation. Arterioscler. Thromb. Vasc. Biol., 1997, 17(1), 188-193.
54. Choi, E.T.; Engel, L.; Callow, A.D.; Sun, S.; Trachtenberg, J.; Santoro, S.; Ryan, U.S. Inhibition of neointimal hyperplasia by blocking alpha V beta 3 integrin with a small peptide antagonist GpenGRGDSPCA. J. Vasc. Surg., 1994, 19(1), 125-134.
55. Ma, X.; O'Brien, E.R. Antagonism of the alpha4 integrin subunit attenuates the acute inflammatory response to stent implantation yet is insufficient to prevent late intimal formation. J. Leukoc. Biol., 2004, 75(6), 1016-1021.
56. Matsuno, H.; Stassen, J.M.; Vermylen, J.; Deckmyn, H. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation, 1994, 90(5), 2203-2206.
57. Srivatsa, S.S.; Fitzpatrick, L.A.; Tsao, P.W.; Reilly, T.M.; Holmes, D.R., Jr.; Schwartz, R.S.; Mousa, S.A. Selective alpha v beta 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin alpha v beta 3 and osteopontin expression during neointima formation. Cardiovasc. Res., 1997, 36(3), 408-428.
58. Shyu, K.G.; Lien, L.M.; Wang, B.W.; Kuan, P.; Chang, H. Resistin contributes to neointimal formation via oxidative stress after vascular injury. Clin. Sci. (Lond), 2011, 120(3), 121-129.
59. Hruban, R.H.; Long, P.P.; Perlman, E.J.; Hutchins, G.M.; Baumgartner, W.A.; Baughman, K.L.; Griffin, C.A. Fluorescence in situ hybridization for the Y-chromosome can be used to detect cells of recipient origin in allografted hearts following cardiac transplantation. Am. J. Pathol., 1993, 142(4), 975-980.
60. Atkinson, C.; Horsley, J.; Rhind-Tutt, S.; Charman, S.; Phillpotts, C.J.; Wallwork, J.; Goddard, M.J. Neointimal smooth muscle cells in human cardiac allograft coronary artery vasculopathy are of donor origin. J. Heart Lung Transplant, 2004, 23(4), 427-435.
61. Glaser, R.; Lu, M.M.; Narula, N.; Epstein, J.A. Smooth muscle cells, but not myocytes, of host origin in transplanted human hearts. Circulation, 2002, 106(1), 17-19.
62. Boersema, M.; Rienstra, H.; van den, H.M.; van, G.H.; van Luyn, M.J.; Navis, G.J.; Popa, E.R.; Hillebrands, J.L. Donor and recipient contribution to transplant vasculopathy in chronic renal transplant dysfunction. Transplantation, 2009, 88(12), 1386-1392.
63. Ma, X.; Hibbert, B.; White, D.; Seymour, R.; Whitman, S.C.; O'Brien, E.R., Contribution of recipient-derived cells in allograft neointima formation and the response to stent implantation. PLoS ONE, 2008, 3(3), e1894.
64. Bader, F.M.; Kfoury, A.G.; Gilbert, E.M.; Barry, W.H.; Humayun, N.; Hagan, M.E.; Thomas, H.; Renlund, D. Percutaneous coronary interventions with stents in cardiac transplant recipients. J. Heart Lung Transplant, 2006, 25(3), 298-301.
65. Gupta, A.; Mancini, D.; Kirtane, A.J.; Kaple, R.K.; Apfelbaum, M.A.; Kodali, S.K.; Marboe, C.; Leon, M.B.; Moses, J.W.; Rabbani, L.E. Value of drug-eluting stents in cardiac transplant recipients. Am. J. Cardiol., 2009, 103(5), 659-662.
66. Stump, M.M.; Jordan, G.L.; DeBakey, M.E.; Halpert, B. Endothelium grown from circulating blood on isolated intravascular dacron hub. Am. J. Pathol., 1963, 43, 361-367.
67. Stump, M.M.; O'Neal, R.M.; Halpert, B.; DeBakey, M.E.; Jordan, G.L. Growth Potential of Circulating Cells in the Peripheral Blood. Surg. Forum, 1963, 14, 301-303.
68. Stump, M.M.; Jordan, G.L.; DeBakey, M.E.; Halpert, B. The endothelial lining of homografts and dacron prostheses in the canine aorta. Am. J. Pathol., 1962, 40, 487-490.
69. Jordan, G.L.; Stump, M.M.; DeBakey, M.E.; Halpert, B. Endothelial lining of dacron prostheses of porcine thoracic aortas. Proc. Soc. Exp. Biol. Med., 1962, 110, 340-343.
70. Florey, H.W.; Greer, S.J.; Poole, J.C.; Werthessen N.T. The pseudointima lining fabric grafts of the aorta. Br. J. Exp. Pathol., 1961, 42, 236-246.
71. Pasquinelli, G.; Preda, P.; Curti, T.; D'Addato, M.; Laschi, R. Endothelialization of a new Dacron graft in an experimental model: light microscopy, electron microscopy and immunocytochemistry. Scanning Microsc., 1987, 1(3), 1327-1338.
72. Feigl, W.; Susani, M.; Ulrich, W.; Matejka, M.; Losert, U.; Sinzinger, H., Organisation of experimental thrombosis by blood cells. Evidence of the transformation of mononuclear cells into myofibroblasts and endothelial cells. Virchows Arch A. Pathol. Anat. Histopathol., 1985, 406(2), 133-148.
73. Campbell, J.H.; Efendy, J.L.; Campbell, G.R. Novel vascular graft grown within recipient's own peritoneal cavity. Circ. Res., 1999, 85(12), 1173-1178.
74. Wu, M.H.; Shi, Q.; Wechezak, A.R.; Clowes, A.W.; Gordon, I.L.; Sauvage, L.R. Definitive proof of endothelialization of a Dacron arterial prosthesis in a human being. J Vasc Surg, 1995, 21(5), 862-867.
75. Campbell, G.R.; Campbell, J.H. The phenotypes of smooth muscle expressed in human atheroma. Ann. NY Acad. Sci., 1990, 598, 143-158.
76. Ferns, G.A.; Raines, E.W.; Sprugel, K.H.; Motani, A.S.; Reidy, M.A.; Ross, R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science, 1991, 253(5024), 1129-1132.
77. Jawien, A.; Bowen-Pope, D.F.; Lindner, V.; Schwartz, S.M.; Clowes, A.W. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J. Clin. Invest., 1992, 89(2), 507-511.
78. Smith, J.D.; Bryant, S.R.; Couper, L.L.; Vary, C.P.; Gotwals, P.J.; Koteliansky, V.E.; Lindner, V. Soluble transforming growth factorbeta type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth. Circ. Res., 1999, 84(10), 1212-1222.
79. Ross, R. Atherosclerosis--an inflammatory disease. N. Engl. J. Med., 1999, 340(2), 115-126.
80. Real, C.; Caiado, F.; Dias, S. Endothelial progenitors in vascular repair and angiogenesis: how many are needed and what to do? Cardiovasc. Hematol. Disord. Drug Targets, 2008, 8(3), 185-193.
81. Albiero, M.; Menegazzo, L.; Avogaro, A.; Fadini, G.P. Pharmacologic targeting of endothelial progenitor cells. Cardiovasc. Hematol. Disord. Drug Targets, 2010, 10(1), 16-32.
82. Yamashita, J.; Itoh, H.; Hirashima, M.; Ogawa, M.; Nishikawa, S.; Yurugi, T.; Naito, M.; Nakao, K.; Nishikawa, S. Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors. Nature, 2000, 408(6808), 92-96.
83. Simper, D.; Stalboerger, P.G.; Panetta, C.J.; Wang, S.; Caplice, N.M. Smooth muscle progenitor cells in human blood. Circulation, 2002, 106(10), 1199-1204.
84. Hibbert, B.; Ma, X.; Pourdjabbar, A.; Simard, T.; Rayner, K.; Jiangfeng, S.; Chen, Y.X.; Filion, L.; O'Brien, E.R., Pre-procedural Atrovastatin Mobilizes Endothelial Progenitor Cells: Clues to the Salutary Effects of Statins on Healing of Stented Human Arteries. PLoS One, 2011, 6(1), e16413.
85. Hibbert, B.; Chen, Y.X.; O'Brien, E.R. c-kit-immunopositive vascular progenitor cells populate human coronary in-stent restenosis but not primary atherosclerotic lesions. Am J Physiol Heart Circ Physiol, 2004, 287(2), H518-H524.
86. Plissonnier, D.; Nochy, D.; Poncet, P.; Mandet, C.; Hinglais, N.; Bariety, J.; Michel, J.B. Sequential immunological targeting of chronic experimental arterial allograft. Transplantation, 1995, 60(5), 414-424.
87. Bigaud, M.; Schraa, E.O.; Andriambeloson, E.; Lobstein, V.; Pally, C.; Kobel, T.; Bruns, C.; Zerwes, H.G. Complete loss of functional smooth muscle cells precedes vascular remodeling in rat aorta allografts. Transplantation, 1999, 68(11), 1701-1707.
88. Perlman, H.; Maillard, L.; Krasinski, K.; Walsh, K. Evidence for the rapid onset of apoptosis in medial smooth muscle cells after balloon injury. Circulation, 1997, 95(4), 981-987.
89. Sata, M.; Maejima, Y.; Adachi, F.; Fukino, K.; Saiura, A.; Sugiura, S.; Aoyagi, T.; Imai, Y.; Kurihara, H.; Kimura, K.; Omata, M.; Makuuchi, M.; Hirata, Y.; Nagai, R. A mouse model of vascular injury that induces rapid onset of medial cell apoptosis followed by reproducible neointimal hyperplasia. J. Mol. Cell Cardiol., 2000, 32(11), 2097-2104.
90. Saiura, A.; Sata, M.; Hirata, Y.; Nagai, R.; Makuuchi, M. Circulating smooth muscle progenitor cells contribute to atherosclerosis. Nat. Med., 2001, 7(4), 382-383.
91. Hillebrands, J.L.; Klatter, F.A.; van den Hurk, B.M.; Popa, E.R.; Nieuwenhuis, P.; Rozing, J. Origin of neointimal endothelium and alpha-actin-positive smooth muscle cells in transplant arteriosclerosis. J. Clin. Invest., 2001, 107(11), 1411-1422.
92. Hillebrands, J.; van den Hurk, B.M.; Klatter, F.A.; Popa, E.R.; Nieuwenhuis, P.; Rozing, J. Recipient origin of neointimal vascular smooth muscle cells in cardiac allografts with transplant arteriosclerosis. J. Heart Lung Transplant., 2000, 19(12), 1183-1192.
93. Diao, Y.; Guthrie, S.; Xia, S.L.; Ouyang, X.; Zhang, L.; Xue, J.; Lee, P.; Grant, M.; Scott, E.; Segal, M.S. Long-term engraftment of bone marrow-derived cells in the intimal hyperplasia lesion of autologous vein grafts. Am. J. Pathol., 2008, 172(3), 839-848.
94. Li, J.; Han, X.; Jiang, J.; Zhong, R.; Williams, G.M.; Pickering, J.G.; Chow, L.H. Vascular smooth muscle cells of recipient origin mediate intimal expansion after aortic allotransplantation in mice. Am. J. Pathol., 2001, 158(6), 1943-1947.
95. Religa, P.; Bojakowski, K.; Maksymowicz, M.; Bojakowska, M.; Sirsjo, A.; Gaciong, Z.; Olszewski, W.; Hedin, U.; Thyberg, J. Smooth-muscle progenitor cells of bone marrow origin contribute to the development of neointimal thickenings in rat aortic allografts and injured rat carotid arteries. Transplantation, 2002, 74(9), 1310-1315.
96. Han, C.I.; Campbell, G.R.; Campbell, J.H. Circulating bone marrow cells can contribute to neointimal formation. J. Vasc. Res., 2001, 38(2), 113-119.
97. Sata, M.; Saiura, A.; Kunisato, A.; Tojo, A.; Okada, S.; Tokuhisa, T.; Hirai, H.; Makuuchi, M.; Hirata, Y.; Nagai, R. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat. Med., 2002, 8(4), 403-409.
98. Shimizu, K.; Sugiyama, S.; Aikawa, M.; Fukumoto, Y.; Rabkin, E.; Libby, P.; Mitchell, R.N. Host bone-marrow cells are a source of donor intimal smooth-muscle-like cells in murine aortic transplant arteriopathy. Nat. Med., 2001, 7(6), 738-741.
99. Tanaka, K.; Sata, M.; Hirata, Y.; Nagai, R. Diverse contribution of bone marrow cells to neointimal hyperplasia after mechanical vascular injuries. Circ. Res., 2003, 93(8), 783-790.
100. Sahara, M.; Sata, M.; Morita, T.; Nakamura, K.; Hirata, Y.; Nagai, R. Diverse contribution of bone marrow-derived cells to vascular remodeling associated with pulmonary arterial hypertension and arterial neointimal formation. Circulation, 2007, 115(4), 509-517.
101. Caplice, N.M.; Bunch, T.J.; Stalboerger, P.G.; Wang, S.; Simper, D.; Miller, D.V.; Russell, S.J.; Litzow, M.R.; Edwards, W.D. Smooth muscle cells in human coronary atherosclerosis can originate from cells administered at marrow transplantation. Proc. Natl. Acad. Sci. USA, 2003, 100(8), 4754-4759.
102. Inoue, T.; Sata, M.; Hikichi, Y.; Sohma, R.; Fukuda, D.; Uchida, T.; Shimizu, M.; Komoda, H.; Node, K. Mobilization of CD34- positive bone marrow-derived cells after coronary stent implantation: impact on restenosis. Circulation, 2007, 115(5), 553-561.
103. Schober, A.; Hoffmann, R.; Opree, N.; Knarren, S.; Iofina, E.; Hutschenreuter, G.; Hanrath, P.; Weber, C. Peripheral CD34+ cells and the risk of in-stent restenosis in patients with coronary heart disease. Am. J. Cardiol., 2005, 96(8), 1116-1122.
104. Hu, Y.; Davison, F.; Ludewig, B.; Erdel, M.; Mayr, M.; Url, M.; Dietrich, H.; Xu, Q. Smooth muscle cells in transplant atherosclerotic lesions are originated from recipients, but not bone marrow progenitor cells. Circulation, 2002, 106(14), 1834-1839.
105. Hillebrands, J.L.; Klatter, F.A.; van Dijk, W.D.; Rozing, J. Bone marrow does not contribute substantially to endothelial-cell replacement in transplant arteriosclerosis. Nat. Med., 2002, 8(3), 194-195.
106. Groenewegen, H.C.; Onuta, G.; Goris, M.; Zandvoort, A.; Zijlstra, F.; van Gilst, W.H.; Rozing, J.; de Smet, B.J.; Roks, A.J.; Hillebrands, J.L. Non-bone marrow origin of neointimal smooth muscle cells in experimental in-stent restenosis in rats. J. Vasc. Res., 2008, 45(6), 493-502.
107. Caplan, A.I. Why are MSCs therapeutic? New data: new insight. J. Pathol., 2009, 217(2), 318-324.
108. az-Flores, L.; Gutierrez, R.; Varela, H.; Rancel, N.; Valladares, F. Microvascular pericytes: a review of their morphological and functional characteristics. Histol. Histopathol., 1991, 6(2), 269-286.
109. Crisan, M.; Deasy, B.; Gavina, M.; Zheng, B.; Huard, J.; Lazzari, L.; Peault, B. Purification and long-term culture of multipotent progenitor cells affiliated with the walls of human blood vessels: myoendothelial cells and pericytes. Methods Cell Biol., 2008, 86, 295-309.
110. Crisan, M.; Yap, S.; Casteilla, L.; Chen, C.W.; Corselli, M.; Park, T.S.; Andriolo, G.; Sun, B.; Zheng, B.; Zhang, L.; Norotte, C.; Teng, P.N.; Traas, J.; Schugar, R.; Deasy, B.M.; Badylak, S.; Buhring, H.J.; Giacobino, J.P.; Lazzari, L.; Huard, J.; Peault, B. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell, 2008, 3(3), 301-313.
111. Canfield, A.E.; Doherty, M.J.; Wood, A.C.; Farrington, C.; Ashton, B.; Begum, N.; Harvey, B.; Poole, A.; Grant, M.E.; Boot-Handford, R.P. Role of pericytes in vascular calcification: a review. Z Kardiol, 2000, 89(S2), 20-27.
112. Malouf, N.N.; Coleman, W.B.; Grisham, J.W.; Lininger, R.A.; Madden, V.J.; Sproul, M.; Anderson, P.A. Adult-derived stem cells from the liver become myocytes in the heart in vivo. Am. J. Pathol., 2001, 158(6), 1929-1935.
113. Aicher, A.; Rentsch, M.; Sasaki, K.; Ellwart, J.W.; Fandrich, F.; Siebert, R.; Cooke, J.P.; Dimmeler, S.; Heeschen, C. Nonbone marrow-derived circulating progenitor cells contribute to postnatal neovascularization following tissue ischemia. Circ. Res., 2007, 100(4), 581-589.
114. Werner, N.; Junk, S.; Laufs, U.; Link, A.; Walenta, K.; Bohm, M.; Nickenig, G., Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ. Res., 2003, 93(2), e17-e24.
115. Sartore, S.; Chiavegato, A.; Faggin, E.; Franch, R.; Puato, M.; Ausoni, S.; Pauletto, P. Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant. Circ. Res., 2001, 89(12), 1111-1121.
116. Shi, Y.; Pieniek, M.; Fard, A.; O'Brien, J.; Mannion, J.D.; Zalewski, A. Adventitial remodeling after coronary arterial injury. Circulation, 1996, 93(2), 340-348.
117. Desmouliere, A.; Geinoz, A.; Gabbiani, F.; Gabbiani, G. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J. Cell Biol., 1993, 122(1), 103-111.
118. Shi, Y.; O'Brien, J.E.; Fard, A.; Mannion, J.D.; Wang, D.; Zalewski, A. Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation, 1996, 94(7), 1655-1664.
119. Scott, N.A.; Cipolla, G.D.; Ross, C.E.; Dunn, B.; Martin, F.H.; Simonet, L.; Wilcox, J.N. Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. Circulation, 1996, 93(12), 2178-2187.
120. Li, G.; Chen, S.J.; Oparil, S.; Chen, Y.F.; Thompson, J.A. Direct in vivo evidence demonstrating neointimal migration of adventitial fibroblasts after balloon injury of rat carotid arteries. Circulation, 2000, 101(12), 1362-1365.
121. Siow, R.C.; Mallawaarachchi, C.M.; Weissberg, P.L. Migration of adventitial myofibroblasts following vascular balloon injury: insights from in vivo gene transfer to rat carotid arteries. Cardiovasc. Res., 2003, 59(1), 212-221.
122. Tomas, J.J.; Stark, V.E.; Kim, J.L.; Wolff, R.A.; Hullett, D.A.; Warner, T.F.; Hoch, J.R. Beta-galactosidase-tagged adventitial myofibroblasts tracked to the neointima in healing rat vein grafts. J. Vasc. Res., 2003, 40(3), 266-275.
123. Hu, Y.; Zhang, Z.; Torsney, E.; Afzal, A.R.; Davison, F.; Metzler, B.; Xu, Q. Abundant progenitor cells in the adventitia contribute to atherosclerosis of vein grafts in ApoE-deficient mice. J. Clin. Invest., 2004, 113(9), 1258-1265.
124. Zhang, L.N.; Wilson, D.W.; da, C., V; Sullivan, M.E.; Vergona, R.; Rutledge, J.C.; Wang, Y.X., Endothelial NO synthase deficiency promotes smooth muscle progenitor cells in association with upregulation of stromal cell-derived factor-1alpha in a mouse model of carotid artery ligation. Arterioscler. Thromb. Vasc. Biol., 2006, 26(4), 765-772.